Zhornitsky, Simon, PhD student, Biomedical Sciences, Science Option Psychiatric
Centre de recherche Fernand-Seguin de l'Hôpital Louis-H. Lafontaine
7331, rue Hochelaga
Montréal (Québec)
H1N 3V2
Téléphone: 514-251-2221, poste 3555
Courriel : szhornitsky@gmail.com
Research Axis
Signatures biologique, psychologique et sociale de la maladie mentale
Study projects
Evolution of substance use, neurological and psychiatric symptoms in schizophrenia and substance use disorder patients: a 12-week, pilot, case–control trial with quetiapine
Abstract
Neurological and psychiatric symptoms are consequences of substance abuse in schizophrenia and non-schizophrenia patients. The present case-control study examines changes in substance abuse/dependence and neurological and psychiatric symptoms in substance abusers with (DD group, n=26) and without schizophrenia (SUD group, n=24) and in non-abusing schizophrenia patients (SCZ group, n=23) undergoing 12-week treatment with the atypical antipsychotic, quetiapine. Neurological and psychiatric symptoms are evaluated with the Positive and Negative Syndrome Scale, the Calgary Depression Scale for Schizophrenia, the Extrapyramidal Symptoms Rating Scale and the Barnes Akathisia Rating Scale.
Publications
Stip E, Zhornitsky S, Potvin S, Tourjman V. Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):997-1000.
Zhornitsky S, Rizkallah E, Pampoulova T, Chiasson JP, Stip E, Rompré PP, Potvin S. Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. J Clin Psychopharmacol. 2010 Aug;30(4):417-24.
Zhornitsky S, Potvin S, Stip E, Rompré PP. Acute quetiapine dose-dependently exacerbates anhedonia induced by withdrawal from escalating doses of d-amphetamine. Eur Neuropsychopharmacol. 2010 Oct;20(10):695-703.
Zhornitsky S, Stip E, Pampoulova T, Rizkallah E, Lipp O, Bentaleb LA, Chiasson JP, Potvin S. Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Mov Disord. 2010 Oct 15;25(13):2188-94.
Benaliouad F, Zhornitsky S, Rompré PP. Evidence that the reward attenuating effect of the D-1-like antagonist, SCH-23390, is not mediated by its agonist action at the 5-HT2c receptors. Behav Brain Res. 2010 Oct 1.
Renaud P, Goyette M, Chartier S, Zhornitski S, Trottier, D, Rouleau J.-L, Proulx, J, Fedoroff P, Bradford J, Dassylva B, Bouchard S. Sexual affordances, perceptual-motor invariance extraction and intentional nonlinear dynamics: sexually deviant and non-deviant patterns in male subjects. Nonlinear Dynamics Psychol Life Sci. 2010 October; 4.
Rizkallah E, Stip E, Zhornitsky S, Pampoulova T, Gendron A, Rompré PP, Chiasson JP, Potvin S. Clinical evolution of substance use disorder patients during treatment with quetiapine: a 12-week, open-label, naturalistic trial. Expert Opin Pharmacother. 2010 Dec;11(18):2947-51.
Zhornitsky S, Potvin S, Moteshafi H, Dubreucq S, Rompré PP, Stip E. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled trials. Int Clin Psychopharmacol. Epub ahead of print.
Zhornitsky S, Potvin S, Aubin G, Stip E. Relationship between insight into cognition, extrapyramidal symptoms, and mental illness in schizophrenia. Aust N Z J Psychiatry. Epub ahead of print.
Zhornitsky S, Stip E, Desfossés J, Pampoulova T, Rizkallah E, Rompré PP, Bentaleb LA, Lipp O, Chiasson JP, Gendron A, Potvin S. Evolution of substance use, neurological and psychiatric symptoms in schizophrenia and substance use disorder patients: a 12-week, pilot, case–control trial with quetiapine. Front Psychiatry. 2:22. doi: 10.3389/fpsyt.2011.00022
Stip E, Zhornitsky S, Moteshafi H, Létourneau G, Stikarovska I, Potvin S, Tourjman A meta-review of ziprasidone for schizophrenia: relationship between pharmacokinetics, pharmacodynamics and clinical profile. Clin Ther. In press.
Zhornitsky S, Jutras-Aswad D, Stip E, Rompré PP, Potvin S. Cocaine and psychosis. In Cocaine abuse: pharmacology, treatment, and relapse prevention. New York: Novascience. Sur invitation. In press.
Fuamba Y, Potvin S, Pampoulova T, Zhornitsky S, Stip E, Côté G, Gobbi G. Cannabis abuse increases aggressive behaviour in patients with psychotic disorders only when combined to alcohol and thoughtless impulsivity. Acta Psychiatr Scand. Submitted.
Zhornitsky S, Stip E. Long-acting injectable or depot antipsychotics for schizophrenia, substance use disorders, and involuntary treatment orders: evidence-based clinical recommendations. Psychiat Serv. Submitted.
Moteshafi H, Zhornitsky S, Brunelle S, Stip E. A meta-analytic comparison of tolerability of olanzapine in schizophrenia and affective disorders. Drug Safety. Submitted.
Zhornitsky S, Aubin G, Desfossés J, Rizkallah E, Pampoulova T, Lipp O, Chiasson JP, Stip E, Potvin S. Cognition is not the best predictor of social functioning in dual-diagnosis schizophrenia. Schizophr Res. Submitted.
ORAL PRESENTATIONS
Zhornitsky S. Acute quetiapine dose-dependently exacerbates anhedonia induced by withdrawal from escalating doses of d-amphetamine. Centre de recherche Fernand-Seguin, April, 2008.
POSTER PRESENTATIONS
Zhornitsky S, Potvin S, Stip E, Rompré PP. Acute quetiapine dose-dependently exacerbates anhedonia induced by withdrawal from escalating doses of d-amphetamine. Journee annuelle de la recherche du centre recherche Fernand-Seguin. May, 2009.
Zhornitsky S, Trottier D, Goyette M, Longpré N, Renaud P. La vidéo-oculographie chez les patients placés en immersion virtuelle: une mesure de préférence sexuelle chez les abuseurs d’enfants. Congres international francophone sur l’agression sexuelle, Montreal, Canada, 2009.
Zhornitsky S, Renaud P, Trottier D, Goyette M, Longpré N. Gaze behavior dynamics in patients placed in virtual immersion: a measure of sexual preference of child sex offenders. 10th annual conference of the International Association of Forensic Mental Health Services, Edinburgh, Scotland, 2009.
Renaud P, Goyette M, Chartier S, Zhornitsky S, Trottier, D, Rouleau J.-L, Proulx, J, Fedoroff P, Bradford J, Dassylva B, Bouchard S. Sexual affordances invariance extraction in sexually deviant and non-deviant subjects. 4th International Nonlinear Science Conference. Palermo, Sicily, 2010.
Zhornitsky S, Stip E, Pampoulova T, Rizkallah E, Lipp O, Bentaleb LA, Chiasson JP, Potvin S. Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Journee annuelle de la recherche du centre recherche Fernand-Seguin. May, 2010.
Rizkallah E, Stip E, Zhornitsky S, Pampoulova T, Gendron A, Rompré PP, Chiasson JP, Potvin S. Clinical evolution of substance use disorder patients during treatment with quetiapine: a 12-week, open-label, naturalistic trial. Journee annuelle de la recherche du centre recherche Fernand-Seguin. May, 2010.
Moteshafi H, Zhornitsky S, Dubreucq S, Rompré PP, Potvin S, Stip E. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled trials. La psychose dans tous ses états. Montreal, Canada, Oct, 2010.
Benaliouad F., Zhornitsky S., Rompré PP. Stimulation of 5-HT2c receptors does not contribute to the attenuation of brain stimulation reward by systemic injection of SCH-23390. 40thannual Meeting of the Society for Neuroscience, San Diego, USA, Nov. 13-17, 2010.
Zhornitsky S, Stip E, Desfossés J, Pampoulova T, Rizkallah E, Rompré PP, Bentaleb LA, Lipp O, Chiasson JP, Gendron A, Potvin S. Neurological and psychiatric symptoms in schizophrenia and substance use disorder patients: a 12-week, case-control trial with quetiapine. 13th International Congress on Schizophrenia Research, Colorado Springs, USA, April 02-06, 2011.
Stavro K, Pelletier J, Zhornitsky S, Potvin S. Significant deficits in problem solving persist throughout the first year of abstinence and slowly begin to remit thereafter. Canadian College of Neuropsychopharmacology. Montreal, May 2011.
Stavro K, Pelletier J, Zhornitsky S, Potvin S. Comparing short to long term deficits of verbal and visual cognitive functions: probing the lateralization hypothesis. Canadian College of Neuropsychopharmacology. Montreal, May 2011.